Alkermes plc reported that Executive Vice President and Chief Operating Officer Jackson Blair Curtis received new equity awards. He was granted stock options for 94,900 shares at an exercise price of $0.00 per share and a restricted stock unit award covering 44,078 shares, both held directly.
The stock options vest and become exercisable in four equal annual installments starting on March 2, 2027. The restricted stock units each represent the right to receive one ordinary share and also vest in four equal annual installments beginning on March 2, 2027, tying a significant portion of his compensation to long-term company performance.
Alkermes plc EVP R&D and Chief Medical Officer Craig C. Hopkinson reported a mix of equity awards, option exercises, and a share sale. He exercised employee stock options for 5,000 ordinary shares at an exercise price of $19.34 per share, then sold 9,000 ordinary shares at a weighted average price of $29.7206 per share in open-market transactions under a Rule 10b5-1 trading plan adopted on 3/14/2025. He also received a new grant of 83,037 employee stock options and a 38,568-share restricted stock unit award, both vesting in four equal annual installments starting 3/2/2027. After these transactions, he directly holds 89,389 ordinary shares of Alkermes.
Alkermes plc executive David Joseph Gaffin, EVP and CLO of Alkermes, Inc., reported a mix of share sales and new equity awards. He sold a total of 4,068 ordinary shares in open-market transactions at $29.29 and $29.76 per share under a pre-arranged Rule 10b5-1 trading plan and held 235,626 shares after the latest sale. He also received a grant of 78,292 stock options and 36,364 restricted stock units, which vest in four equal annual installments starting on March 2, 2027.
Alkermes plc receipt of a Rule 144 notice indicates a proposed sale of 2,034 shares of common stock. The filing lists the issuer as Alkermes plc, the filer name David Gaffin, and a transaction date of 03/03/2026 on NASDAQ.
The filing also lists vesting entries for restricted stock unit and performance share unit awards dated 03/03/2017, 03/03/2018, 05/28/2015, and 10/05/2015, and notes a prior sale by the filer on 03/02/2026.
Alkermes plc submitted a Rule 144 notice reporting 6,000 shares of Common Stock to be sold with an aggregate price of $180,000.00; the filing lists beneficial ownership of 166,649,934 shares as of 03/02/2026. The filing also lists recent vesting of restricted stock units: 897 on 02/23/2025, 3,952 on 02/22/2025, and 1,151 on 02/18/2025.
Alkermes plc submitted a Form 144 reporting an intended sale of Common Stock on 03/02/2026 in connection with NASDAQ‑listed shares. The filing lists restricted stock unit vestings from 03/03/2017 (322 shares) and 02/17/2018 (1,712 shares) as sources of the shares.
Alkermes plc reported an insider Form 144 filing showing intended dispositions of ordinary shares by a reporting person and multiple recent sales. The filing lists proposed sales/exercises on 03/02/2026 and vesting on 02/05/2026, and records past sales by Craig Hopkinson totaling multiple transactions in Dec 2025–Feb 2026.
The entries include broker-assisted cashless exercise transactions of 5,000 shares and a performance-vesting of 4,000 shares; several open-market sales by Craig Hopkinson are listed with individual share counts and proceeds.
Alkermes plc vice president of finance Samuel Joseph Parisi reported equity transactions involving restricted stock units and ordinary shares. On February 26, 2026, he acquired 2,747 ordinary shares through the exercise/conversion of a restricted stock unit award, with each unit representing one ordinary share. Following this, a separate transaction disposed of 808 ordinary shares at $30.73 per share to cover tax obligations, leaving him with 14,607 ordinary shares held directly. The underlying restricted stock unit award vests in four equal annual installments beginning on February 26, 2025.
Alkermes plc SVP and Chief Commercial Officer Christian Todd Nichols reported equity award activity involving restricted stock units and ordinary shares. On 2026-02-26, he exercised 5,410 restricted stock units, which converted into 5,410 ordinary shares at a stated price of $0.0000 per share.
A related Form 4 line shows 2,403 ordinary shares disposed of at $30.73 per share in a code F transaction, which reflects shares withheld to satisfy tax obligations rather than an open-market sale. After these transactions, Nichols directly owned 115,769 ordinary shares and held 10,819 restricted stock units, each representing a contingent right to receive one ordinary share. The restricted stock unit award vests in four equal annual installments beginning on 02/26/2025.
Alkermes plc EVP and COO Jackson Blair Curtis reported equity compensation-related transactions. On February 26, 2026, he acquired 8,322 ordinary shares upon the exercise of a restricted stock unit award, with each unit representing one ordinary share. On the same date, 3,695 ordinary shares were disposed of at $30.73 per share to satisfy tax withholding obligations. Following these transactions, Curtis directly owned 241,308 ordinary shares. The underlying restricted stock units vest in four equal annual installments beginning on February 26, 2025.